Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling ...

Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy ofOxford BioDynamics' EpiSwitch blood-based Colorectal No-Stool Test (NST) High ...